Medpace Holdings (MEDP) Notes Payables (2022 - 2023)
Medpace Holdings' (MEDP) quarterly Notes Payables came in at $55.0 million in Q2 2023, down 77.97% on a YoY basis from $249.7 million in Q2 2022, and down 52.17% quarter-over-quarter from $115.0 million in Q1 2023.
Powered by 
Analysis
Medpace Holdings (MEDP) Notes Payables (2022 - 2023) Analysis & Trends
Medpace Holdings (MEDP) has reported Notes Payables for 2 consecutive years, with $55.0 million the latest figure, recorded in Q2 2023.
- For the quarter ending Q2 2023, Notes Payables fell 77.97% year-over-year to $55.0 million; the trailing twelve-month figure through Jun 2023 stood at $55.0 million (down 77.97% YoY), and the FY2022 full-year result was $50.0 million, changed N/A from the prior year.
- Notes Payables fell to $55.0 million in Q2 2023 per MEDP's latest filing, from $115.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $249.7 million in Q2 2022 and bottomed at $50.0 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 55.00 Mn |
| Mar 31, 2023 | 115.00 Mn |
| Dec 31, 2022 | 50.00 Mn |
| Sep 30, 2022 | 139.70 Mn |
| Jun 30, 2022 | 249.70 Mn |